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understanding and keeping “the enemy” close, this
may lead to a new standard of partnership that will
result in benefits for our patients.
Note: Dr. Hayden has no relationships with any
pharmaceutical or biomedical companies, has received
no research funding from industry sources, and does
not participate in any industry sponsored speakers
bureau.
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It is time to stop hiding our heads in the sand when
it comes to interactions with the pharmaceutical
industry!  This is an issue of reality, not ideology.  In
an ideal world there would be no industry
sponsored research and no potential for tainted
research.  In an ideal world there would be no need
for marketing of new drugs to physicians or to the
public and all the savings would be passed on to
consumers.  In an ideal world there would also be
no crime, no disease (and no doctors), and no war;
everyone would look like they just walked off the
set of Baywatch, and no one would have to work
unless they wanted to!  The reality is that there is
not enough money in all the governments or
independent organizations in the world to fund the
all research that is necessary, and so some funding
must also come from the pharmaceutical industry.  It
is also reality that marketing campaigns work,
whether it be to physicians or to the lay public.  It is
time to stop the rhetoric about conspiracy theory
(what I sometimes hear people say would make a
good episode for the X-Files) and get down to the
business of creating a framework that will in every
possible manner limit bias and maximize objectivity
in conducting, reporting, and using the results of
clinical trials.  Whether as investigators or educators
in emergency medicine, interaction with the
pharmaceutical industry is inevitable.  Rather than
attempting to naively avoid it, we can use such
interactions to enforce ethical conduct and scientific
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rigor in research, as well as to teach EM residents
and students the principles of critical appraisal and
critical thinking.
At present, more than 70% of funding for clinical trials
comes from the pharmaceutical industry.1 Even if vast
increases in government and foundation funding
sources were possible, elimination of industry funding
of research entirely would mean that a great deal of
very worthy research would not be completed; patients
would ultimately suffer from lack of progress in treating
many disease conditions.  Realizing that at least a
portion of funding for important research must come
from the pharmaceutical industry, the Society for
Academic Emergency Medicine (SAEM) published
a set of guidelines in 19952 in an attempt to set ethical,
scientific, and professional standards for academic EM
investigator involvement in clinical trials sponsored by
industry.  This was a rational approach to the issues,
providing a framework for research that essentially
promotes unrestricted collection and interpretation of
data, open sharing of data from research studies, and
unrestricted publication of sponsored clinical trials.
These guidelines will not eliminate potential influence
on research, but rather they will offer a practical
solution that encourages the highest scientific integrity.
In a recent article Reed and Camargo3 suggest going
even further than the original guidelines and
distinguishing between industry initiated research and
investigator initiated research with industry support.
The latter would be the preferred option, when
possible, because it can optimize the unrestricted use
of financial support and independence of the study
investigators.  Reed and Camargo suggest the
following methods can be employed to minimize
industry influence:
panels to assess the scientific merit of the design and
implementation of the study.
2. Creation of independent data centers to house
study databases and an independent monitoring
committee that will have the discretion to continue
enrolling patients until preplanned parameters are
met, or stop a study before data collection is
complete for safety reasons.  In this manner, trials
cannot be stopped by either pharmaceutical
companies or investigators if interim analyses show
results that may not favor the specific interests of
industry or investigators.
3. Avoiding or renegotiating contracts to eliminate
“gag” clauses or the ability to suppress any of the
results.  Furthermore, publication of all results must
be guaranteed even if the results of the study are
negative.
4.    Exclusivity contracts should be avoided in
large multicenter investigations (such contracts would
attempt to limit enrollment of eligible patients into
the sponsored study only, thereby restrict patients
from receiving benefit from other trials being
simultaneously conducted at that site).
5. Emergency medicine researchers should be
on the steering committee from the outset in any large
trial sponsored or initiated by industry.
6. Require independent IRB approval for all
clinical trials.
7. Require full disclosure of funding sources
during all phases of the study including publication.
As Rothman4 put it, “open, rational criticism and an  1. Development of independent study reviewPage  67 The California Journal of Emergency Medicine IV:1,Jul-Oct 2003
evaluation based on the study’s merit is the only fair
way to proceed.”  While the pharmaceutical industry
often gets bashed for undue influence, in reality most
representatives in the industry are concerned about
these issues as well, and in fact, the industry recently
published a set of guidelines on the subject.5
Perhaps the strongest argument in favor of continuing
involvement of academic researchers in industry
research is the growing number of private, for profit
Contract Research Organizations (CROs), and Site
Management Organizations (SMOs).  The
pharmaceutical industry is increasingly utilizing such
entities instead of academic institutions/investigators
because of lower costs and often greater productivity
that stems from less red tape.  In the last 10 years the
amount of industry money going to academic medical
centers for research has dropped from 80% to 40%
in favor of CROs and SMOs.6 There is great concern
that industry has even greater potential to influence
the conduct of such trials than trials with academic
medical centers.  Academic investigators must
maintain a prominent role in industry research to ensure
that clinical trials are conducted with the highest degree
of scientific merit and ethics.
Researchers in emergency medicine are not alone in
their interactions with the pharmaceutical industry.  As
educators in emergency medicine, instead of
disappearing when drug reps come around or barring
them from coming within 100 feet of our residents,
we can use interactions and materials provided by
drug companies to teach residents and students the
principles of critical appraisal.  The issue, of course,
is one of conflict of interest.  The dictionary defines
conflict of interest as the circumstance of an individual
whose personal interests might benefit from his or her
official actions or influence.  It is certainly possible,
and in fact the literature supports the notion that
interactions with pharmaceutical representatives can
influence physician behavior.  However, I believe we
should teach our residents conflict resolution, not
complete conflict avoidance!  It does our residents
little good to for us to be overprotective.  Someday,
they will graduate and have to deal with promotional
materials and individuals from pharmaceutical
companies or perform industry-sponsored research.
Arming both researchers and end users of the results
of clinical trials with the skills necessary to separate
marketing from evidence will allow them to make up
their own minds, avoid potential conflict of interest,
and become educated consumers/investigators.
Let us take a few examples of how to make interactions
or advertisements into teaching moments.  Anyone
who has seen the back cover of the Annals of
Emergency Medicine lately will recognize the familiar
“Shock N Load” ad campaign for Amiodarone; “Now
Instead of Lidocaine”.  One of the ads states “29
percent more people in cardiac arrest reached the
hospital alive thanks to Cordarone IV”.   After seeing
a copy of the Annals lying on top of one of my residents’
mail piles, I asked her what she knew about the
ARREST Trial.7  After it became clear that she was
only familiar with the results as stated in the ad, we
proceeded to briefly analyze the original article.  In
this randomized placebo controlled trial of Amiodarone
in prehospital victims of ventricular fibrillation (V Fib),
44% in the Amiodarone group, compared to 34% in
the placebo group made it to hospital admission with
vital signs.  By simple division (44%/34%), the relative
risk difference is 29%; however, the absolute risk
difference between the two groups is only 10%.  Ten
victims of prehospital V Fib arrest need to be treated
with Amiodarone compared to placebo in order for
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with vital signs.  This is the first teaching point you can
make to your residents; drug company advertisements
often will present results as a relative risk difference
instead of the more clinically relevant absolute risk
difference in order to make the results look better.  I
then asked my resident if this result is important and
she told me yes, but not as important as whether these
patients survive to hospital discharge.  In the ARREST
Trial, survival to hospital discharge in the placebo
group was 13.2% and in the Amiodarone group
13.4% (p=NS).  Even if the study was large enough
that this difference was statistically significant, the
absolute benefit difference is 0.2%, which means that
500 victims of prehospital V Fib arrest need to be
treated with Amiodarone in order for one additional
patient to survive to hospital discharge!  Interesting
that the advertisement in the Annals did not present
the results in this manner.  This is essentially the critical
appraisal issue of choosing the right outcome to
measure and report.  We then proceeded to have a
debate over whether it is better to first have patients
make it to hospital admission so that they may have
some increased chance of surviving to hospital
discharge, or whether using Amiodarone in the field
may actually result in increased utilization of critical
care resources for no significant improvement in the
most important outcome.  It became obvious in this
case that the evidence alone does not make the clinical
decision for you; rather it must be taken in
consideration along with physician and patient values
and clinical circumstances.  That is a lot of teaching
points from one advertisement.  What a wonderful
learning experience came from simply using literature
supplied by a pharmaceutical company to teach critical
appraisal skills!
Good clinical teachers look for every opportunity to
exploit a teaching moment.  As educators in EM it is
our responsibility to seek these for our residents and
model the ethical and professional behavior that we
want them to develop.  If our residents never have
the opportunity to see a seasoned clinician use such
circumstances for teaching or modeling behavior, then
an important facet of their education is lost.  Recently,
in my own ED, a police and paramedics brought in a
combative young male who required immediate
chemical sedation in order to protect the patient and
staff.  My senior EM resident was busy with a cardiac
patient at that moment so I ordered the customary 5
mg intramuscular Haloperidol and 2 mg of
Lorazepam. Almost before I hit the enter key on the
computer, the nurses came to me and said “Steve,
you are killing us! The Geodon drug rep is in the
nurses’ lounge right now with lunch and she told us
that there is an article that says Geodon is better than
Haldol for acute agitation, so we have to give this
patient Geodon.”  My senior EM resident had just
come up at this point to see what was going on with
this new patient and looked at me with a sly smile
when the nurse made this statement.
Some educators in EM would say that the drug rep
should never have been allowed in the ED in the first
place, so that these kinds of situations do not disrupt
our clinical practice.  I believe, however, that this is
an opportunity to be seized for teaching.  Rather than
going ballistic (which was very tempting), I calmly
explained to the nurses and EM residents in earshot
that I had just reviewed the article they referred to
with one of our toxicologists and that the patients
entered into the Brook study8 were patients admitted
to a psychiatric unit.  The relevant endpoints were
measured at the end of three days of treatment, not
after the first dose or two, and therefore we did not
know from this study how well Geodon compared to
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in the ED.  I then asked the nurses to look at the
patient we were currently taking care of and note that
it was taking three police officers to restrain him with
a spit rag on his face.  I asked the nurses if he was in
a state where they would be able to do an appropriate
informed consent for a research study and they all
laughed.  I then pointed out to them that every patient
entering into the Brook study was in a condition in
which they were able to give informed consent before
receiving medications.  This really made a big
impression, as I pointed out to them the results of the
Brook study may not apply to our patients in the ED.
Lastly, I informed the nurses that the study also
excluded patients suspected of being under the
influence of alcohol or any drug of abuse and patients
who had a history of substance abuse in the past couple
of months.  The nurses laughed again and noted that
that would exclude virtually every ED patient who
requires acute chemical sedation.  I told my senior
resident that this was an issue of applicability, and
that while the Geodon study was nicely designed, the
patient population was just too dissimilar to directly
apply the results to our patients in the ED.
Furthermore, I had no objection and in fact would be
interested in using Geodon for acutely combative
patients in the ED, but that it had not been studied
well enough to date.   My resident suggested that this
might make an interesting research project.  At that
point, the nurse taking care of the patient smiled and
said she had better go draw up the Haloperidol and
Lorazepam so the police officers could take a break
from restraining the patient.  Before she left, she said
that she would be interested in helping out in such a
study, and a couple of the other nurses nodded their
heads in agreement.  What a terrible shame it would
have been to lose a teaching moment like this by
avoiding all contact with pharmaceutical
representatives.
My resident and the nurses all learned a lot that day.
It was an opportunity to model behavior skills to my
resident in handling the nurses in the ED, deal with
issues of conflict of interest, and ultimately lead to the
development of collaborative research in the ED
between our nurses and EM residents.  That is a lot
for a five minute teaching moment stimulated by an
encounter with a pharmaceutical representative!
Lee Goldman has been quoted as saying, “companies
translate biologic advances into usable products for
patients.  They do it for a profit motive, but they do it
and it needs to be done.”9 This is reality, and instead
of avoiding all exchanges, it is up to the academic
community in EM to develop strategies to interact
ethically, professionally and to promote the highest
ideals of education and scientific merit in interactions
with the pharmaceutical industry.
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